Lincidio Perez
Overview
Explore the profile of Lincidio Perez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morera-Diaz Y, Gavilondo J, Bequet-Romero M, Ramirez J, Hernandez-Bernal F, Selman-Housein K, et al.
Semin Oncol
. 2018 Oct;
45(1-2):68-74.
PMID: 30318086
HEBERSaVax is a cancer therapeutic vaccine candidate based on the combination of a recombinant antigen representative of human vascular endothelial growth factor (VEGF), and clinically tested adjuvants. The vaccine has...
2.
Morera Y, Gonzalez R, Lamdan H, Perez L, Gonzalez Y, Aguero J, et al.
Exp Eye Res
. 2014 Mar;
122:102-9.
PMID: 24675387
Vascular Endothelial Growth Factor (VEGF) is a key driver of the neovascularization and vascular permeability that leads to the loss of visual acuity of eye diseases like wet age-related macular...
3.
Lamdan H, Gavilondo J, Munoz Y, Pupo A, Huerta V, Musacchio A, et al.
Mol Biosyst
. 2013 May;
9(8):2097-106.
PMID: 23702826
We have previously reported the isolation of a novel single-chain variable fragment (scFv) against vascular endothelial growth factor (VEGF), from a phage-displayed human antibody repertoire. This scFv, denominated 2H1, was...
4.
Rodriguez M, Perez L, Gavilondo J, Garrido G, Bequet-Romero M, Hernandez I, et al.
Plant Biotechnol J
. 2012 Oct;
11(1):53-65.
PMID: 23046448
A broad variety of foreign genes can be expressed in transgenic plants, which offer the opportunity for large-scale production of pharmaceutical proteins, such as therapeutic antibodies. Nimotuzumab is a humanized...
5.
Ayala M, Gavilondo J, Rodriguez M, Fuentes A, Enriquez G, Perez L, et al.
Methods Mol Biol
. 2009 Feb;
483:103-34.
PMID: 19183896
Because of the wide use and high demand in medicine, monoclonal antibodies are among the main recombinant pharmaceuticals at present, although present limitations of the productive platforms for monoclonal antibodies...
6.
Pujol M, Gavilondo J, Ayala M, Rodriguez M, Gonzalez E, Perez L
Trends Biotechnol
. 2007 Sep;
25(10):455-9.
PMID: 17869360
Cancer is one of the most prevalent diseases worldwide, which explains why biological therapies for cancer are forecast to make up 35% of total recombinant pharmaceuticals by 2010. Because of...
7.
Sanchez A, Ramos Y, Solano Y, Gonzalez L, Besada V, Betancourt L, et al.
Rapid Commun Mass Spectrom
. 2007 Jun;
21(14):2237-44.
PMID: 17569096
We report here a method for the identification of free or blocked N-terminal peptide of in-gel digested isolated proteins. The primary amino groups of the gel-entrapped protein are blocked with...
8.
Perez L, Ayala M, Pimentel G, Bell H, Canaan-Haden L, Bequet M, et al.
Biotechnol Appl Biochem
. 2005 Aug;
43(Pt 1):39-48.
PMID: 16101587
In the present paper we report the development of a bivalent scFv (single-chain Fv) antibody fragment, starting from a mouse mAb (monoclonal antibody) specific for CEA (carcinoembryonic antigen) that has...
9.
Rodriguez M, Ramirez N, Ayala M, Freyre F, Perez L, Triguero A, et al.
Biotechnol Bioeng
. 2004 Dec;
89(2):188-94.
PMID: 15584026
When generating stably transformed transgenic plants, transient gene expression experiments are especially useful to rapidly confirm that the foreign molecule of interest is correctly assembled and retains its biological activity....